NOX-H94

TME Pharma AG · Phase 2 active Small molecule

At a glance

Generic name	NOX-H94
Also known as	lexaptepid pegol
Sponsor	TME Pharma AG
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NOX-H94 (PHASE1)
Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis Patients (PHASE1, PHASE2)
Pharmacokinetics/Pharmacodynamics of NOX-H94 in the Human Endotoxemia Model (PHASE1)
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NOX-H94 CI brief — competitive landscape report
NOX-H94 updates RSS · CI watch RSS
TME Pharma AG portfolio CI